Monday, October 3, 2022


Biotechnology News Magazine

MIMEDX Announces Launch of AMNIOEFFECT

ew Product Enables Company to Target Additional Surgical Procedures and Deepen Market Penetration in the Growing $1B Surgical Recovery Market

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the launch of AMNIOEFFECT™, a tri-layer PURION® processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.

AMNIOEFFECT complements and expands the Company’s Surgical Recovery product portfolio. In addition, AMNIOEFFECT offers superior handling characteristics and provides surgeons the capability to secure the tissue in place with sutures when needed to address a surgical wound. During the Limited Market Release (LMR) phase, AMNIOEFFECT was used in over 50 surgical cases. Early experience has shown that the product’s handling characteristics, thickness and broad size availability are important in large debridement, limb salvage, lumbar fusion and gynecological procedures.

“The Surgical Recovery market is an engine of growth for MIMEDX,” said Rohit Kashyap, Ph.D., MIMEDX President, Wound Care & Surgical. “Our LMR experience with more than 20 surgeons confirmed that AMNIOEFFECT services tangible unmet needs. I am encouraged by the strong level of physician interest the product has generated and confident that AMNIOEFFECT will play a defined role in the physician tool kit. We are committed to broadening our product offering to drive deeper penetration and achieve above-market growth.”

“I am optimistic about the potential utility of AMNIOEFFECT within an array of surgical procedures,” said Dr. Nicolas Mouawad, Chief of Vascular & Endovascular Surgery, McLaren Health System – Bay Region, Bay City, Michigan and a participant in the AMNIOEFFECT LMR. “The field of placental tissue holds tremendous promise for physicians in need of advanced treatment options for patients presenting with multiple comorbidities that can contribute to surgical complications, delayed healing, and added cost to the healthcare system. Given the product’s thicker configuration and availability in larger sizes, we will be able to treat patients needing greater coverage more effectively and efficiently in the operating room, particularly those with difficult-to-close surgical wounds.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine